This is the authors' abstract. We don't add key points for this paper.
The sincerest form of flattery! A novel, symmetric lipid A mimetic (D1) formed by two glucose units linked through a 6-6' succinic diamide linker is active in modulating the activity of human TLR4. D1 inhibits endotoxin-stimulated TLR4 activation by inhibiting interaction of endotoxin with both receptors CD14 and MD-2 (associated to TLR4). D1 also has weak TLR4 agonist activity that makes it a promising lead compound for development as a vaccine adjuvant.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Piazza et al. (2011) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: